MedTrace Logo

Stem Cells in Spinal Cord Injury

NCT03935724 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2023-09-29

No results posted yet for this study

Summary

This is a multicenter, randomized, double-blind, placebo-controlled and delayed-start phase II/III clinical study.

Conditions

  • Spinal Cord Injuries
  • Acute Spinal Cord Injury
  • Paraplegia, Spinal
  • Paraplegia; Traumatic

Interventions

BIOLOGICAL

Neuro-Cells

Neuro-Cells is an autologous fresh stem cells containing product which modulates the secondary inflammation following a TSCI, reduces apoptosis (cell death) in the injured spinal cord, reduces scar tissue formation in the damaged spinal cord and creates a cell regenerative environment in the injured spinal cord.

Sponsors & Collaborators

  • Neuroplast

    lead INDUSTRY

Principal Investigators

  • Antonio Oliviero, MD · Hospital Nacional de Parapléjicos de Toledo

  • Fin Biering-Soerensen, MD · Righospitalet

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-18
Primary Completion
2024-02-01
Completion
2024-08-01

Countries

  • Denmark
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03935724 on ClinicalTrials.gov